查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553610

心絞痛藥物市場規模、佔有率、趨勢分析報告：按類型、藥物類別、分銷管道、地區和細分市場預測，2024-2030

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

心絞痛藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球心絞痛藥物市場規模預計將達到157.1億美元，2024年至2030年複合年成長率為4.0%。

全球心絞痛市場是由對緩解疾病和標靶治療的需求、醫療保健支出的增加以及新興市場有效治療方法的可用性所推動的。

此外，心絞痛盛行率和發病率的上升預計將推動市場成長。在美國、英國、德國、法國、義大利、西班牙和日本等新興市場，慢性穩定型狹心症的盛行率為2.0%至4.0%。男性和女性心絞痛盛行率均隨年齡增加而快速增加，其中男性45至54歲為2.0至5.0%，男性65至74歲為10.0至20.0%，女性45至54歲為0.1至1.0% %， 74 歲時為65 - 10.0 至15.0%。這種疾病的症狀可以透過健康的生活方式來控制。

心絞痛藥物市場亮點

  • 在心絞痛藥物市場中，穩定型心絞痛領域2023年佔銷售額的52.2%。患有慢性穩定型狹心症的患者數量正在增加，其中近一半將其發展為缺血性心臟疾病的早期症狀。
  • 2023年， BETA阻斷劑在心絞痛市場佔有主導地位，銷售佔有率為38.8%。該細分市場的成長主要是由於其擴大被用作心絞痛的一線治療藥物。
  • 收益佔有率%。這是因為在基礎設施先進、設備充足的醫院中，尋求心絞痛治療的患者數量不斷增加。
  • 北美心絞痛藥物市場主導全球心絞痛藥物市場，2023年收益佔有率超過40.0%。對微創治療的需求不斷成長預計將在預測期內推動市場成長。
  • 亞太地區心絞痛藥物市場預計將以 5.5% 的複合年成長率在全球心絞痛藥物市場中成長最快。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章心絞痛藥物市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 心絞痛藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章心絞痛藥物市場：按類型估計和趨勢分析

  • 細分儀表板
  • 心絞痛藥物市場：2023 年和 2030 年按類型分類的變化分析
  • 穩定型心絞痛
  • 不穩定型心絞痛
  • 微血管性心絞痛
  • 變異型心絞痛

第5章心絞痛藥物市場：依藥物類別估計與趨勢分析

  • 細分儀表板
  • 心絞痛藥物市場：2023 年和 2030 年按藥物類別分類的波動分析
  • BETA受體阻斷劑
  • 鈣拮抗劑
  • 硝酸鹽
  • 抗凝血物
  • 抗血小板藥物
  • 其他藥物類別

第6章心絞痛藥物市場：依通路估算與趨勢分析

  • 細分儀表板
  • 心絞痛藥物市場：2023 年和 2030 年按分銷管道分類的波動分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章心絞痛藥物市場：區域估計與趨勢分析

  • 2023 年及 2030 年心絞痛藥物市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Pfizer Inc.
    • Bayer AG
    • AstraZeneca
    • Gilead Sciences
    • Novartis AG
    • GlaxoSmithKline Plc.
    • Merck &Co., Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Otsuka Pharmaceutical Co., Ltd.
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
簡介目錄
Product Code: GVR-2-68038-045-3

Angina Pectoris Drugs Market Growth & Trends:

The global angina pectoris drugs market is expected to be valued at USD 15.71 billion by 2030, registering a CAGR of 4.0% from 2024 to 2030, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.

Angina Pectoris Drugs Market Report Highlights:

  • The stable angina segment dominated the angina pectoris drug market with a revenue share of 52.2% in 2023. The number of patients suffering from chronic stable angina is rising, and almost half of these patients have it as the initial sign of ischemic heart disease.
  • Beta blockers dominated the angina pectoris market in 2023 with a revenue share of 38.8%. Segment growth is primarily driven by its increasing adoption as a first-line therapy for angina pectoris.
  • Hospital pharmacies dominate the angina pectoris drugs market with a revenue share of 48.5% in 2023. This can be attributed to the fact that hospitals equipped with advanced infrastructure and suitable facilities are witnessing a rise in the number of patients seeking treatment for angina pectoris disorders.
  • North America angina pectoris drugs market dominated the global angina pectoris drugs market with a revenue share of over 40.0% in 2023. The increasing demand for minimally invasive procedures is expected to drive the market's growth in the forecast period.
  • Angina pectoris drugs market in Asia Pacific is expected the fastest growth in the global angina pectoris drugs market with a CAGR of 5.5%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Angina Pectoris Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Angina Pectoris Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Stable Angina
    • 4.3.1. Stable Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Unstable Angina
    • 4.4.1. Unstable Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Microvascular Angina
    • 4.5.1. Microvascular Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Prinzmetal Angina
    • 4.6.1. Prinzmetal Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Angina Pectoris Drugs Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Beta Blockers
    • 5.3.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Calcium Antagonists
    • 5.4.1. Calcium Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Nitrates
    • 5.5.1. Nitrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Anticoagulants
    • 5.6.1. Anticoagulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Anti-Platelets
    • 5.7.1. Anti-Platelets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Drug Classes
    • 5.8.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Angina Pectoris Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Angina Pectoris Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Gilead Sciences
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. GlaxoSmithKline Plc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Amgen Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Eli Lilly and Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Otsuka Pharmaceutical Co., Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Sanofi S.A.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives
    • 8.4.12. Boehringer Ingelheim International GmbH
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/Strategic Initiatives